Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Vistagen Therapeutics (VTGN) Other Operating Expenses (2020 - 2024)

Vistagen Therapeutics' Other Operating Expenses history spans 9 years, with the latest figure at -$1000.0 for Q3 2025.

  • For Q3 2025, Other Operating Expenses changed N/A year-over-year to -$1000.0; the TTM value through Dec 2025 reached -$1000.0, down 266.67%, while the annual FY2021 figure was $25700.0, 99.85% down from the prior year.
  • Other Operating Expenses for Q3 2025 was -$1000.0 at Vistagen Therapeutics, down from $600.0 in the prior quarter.
  • Across five years, Other Operating Expenses topped out at $4.5 million in Q4 2023 and bottomed at -$550700.0 in Q1 2021.
  • The 4-year median for Other Operating Expenses is $600.0 (2024), against an average of $797320.0.
  • The largest YoY upside for Other Operating Expenses was 250.0% in 2021 against a maximum downside of 137775.0% in 2021.
  • A 4-year view of Other Operating Expenses shows it stood at $700.0 in 2021, then surged by 648042.86% to $4.5 million in 2023, then crashed by 99.99% to $600.0 in 2024, then tumbled by 266.67% to -$1000.0 in 2025.
  • Per Business Quant, the three most recent readings for VTGN's Other Operating Expenses are -$1000.0 (Q3 2025), $600.0 (Q1 2024), and $4.5 million (Q4 2023).